1.60
+0.1(+6.67%)
Currency In USD
| Previous Close | 1.5 |
| Open | 1.52 |
| Day High | 1.64 |
| Day Low | 1.51 |
| 52-Week High | 3.31 |
| 52-Week Low | 1.01 |
| Volume | 978,176 |
| Average Volume | 1.16M |
| Market Cap | 453.87M |
| PE | -4.1 |
| EPS | -0.39 |
| Moving Average 50 Days | 1.48 |
| Moving Average 200 Days | 1.78 |
| Change | 0.1 |
If you invested $1000 in Erasca, Inc. (ERAS) since IPO date, it would be worth $91.8 as of August 23, 2025 at a share price of $1.6. Whereas If you bought $1000 worth of Erasca, Inc. (ERAS) shares 3 years ago, it would be worth $179.78 as of August 23, 2025 at a share price of $1.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001
GlobeNewswire Inc.
Jun 02, 2025 12:00 PM GMT
Both ERAS-4001 and potential best-in-class pan-RAS molecular glue ERAS-0015 received IND clearance in May ahead of company guidance Initial Phase 1 monotherapy data for both RAS-targeting programs expected in 2026 SAN DIEGO, June 02, 2025 (GLOBE NE
Erasca to Present at Upcoming Investor Conferences in June
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, tod
Erasca Reports First Quarter 2025 Business Updates and Financial Results
GlobeNewswire Inc.
May 13, 2025 8:05 PM GMT
Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, a